in end-stage renal disease (ESRD) patients, with relief of anemia symptoms, improved quality of life, and decreased blood transfusion rates. (2, 3) Previous randomized clinical trials analyzed by an intentionto-treat approach have not shown benefits in maintaining physiologically normal hemoglobin levels in hemodialysis and chronic kidney disease patients and have reported an increase in cardiovascular events and complications associated with both higher and lower hemoglobin levels. (4) (5) (6) The target of a "normal" hemoglobin range in ESRD and chronic kidney disease patients remains to be elucidated. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative has developed clinical guidelines for targeting heemoglobin levels between 11-12 g/dL for patients with ESRD. (7) Several studies showed that about 30-38% of patients maintain this range at any point of time. (7, 8) Fishbane and Berns describe the phenomenon of hemoglobin fluctuation and cycling passing through the target range in contrast to healthy individuals in whom hemoglobin levels are maintained in a narrow physiological range. In clinical practice, (9) the ESA dosage is often adjusted according to the mean hemoglobin level and hemoglobin cycling and haemoglobin excursions (definition: half of hemoglobin cycling duration) are ignored. (9) Different methods have been used to quantify the degree of hemoglobin variability but currently, none of the previously described methods reflect all aspects of variability. (10) (11) (12) (13) One promising method for assessing hemoglobin levels is the use of distinct categories of hemoglobin level changes compared with the target level over a 6-month period. (10) This approach makes it easier to quantify hemoglobin variability trends in clinical practice.
Large population-based studies of hemoglobin variability performed in hemodialysis and chronic kidney disease patients have revealed an association with decreased survival, comorbidity, and hospitalizations. (10, 11, 14, 15) However, a recent study reported that hemoglobin variability did not independently predict mortality in European hemodialysis patients. (16) There have been no related hemoglobin variability studies in peritoneal dialysis patients, who have less blood loss with less impact on hemoglobin levels than hemodialysis patients. The aims of our study were to analyze the effects of hemoglobin variability in peritoneal dialysis patients at a single medical center and to assess any difference between the hemodialysis and peritoneal dialysis populations.
METHODS
This clinical study followed the Declaration of Helsinki and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital. The institutional review board approval number is 98-2062B. The study subjects included patients undergoing outpatient peritoneal dialysis at Chang Gung Memorial Hospital Medical Center, Linkou. For the retrospective part of the study, we reviewed patient histories since January 1, 2008 (n = 405). We then observed patients who were maintained on peritoneal dialysis (excluding those who dropped out, transferred to other hospitals, or died) for a further 3 months. These patients (n = 390) were further followed for the duration of the inclusion period of 6 months (April 1, 2008 to September 30, 2008). Finally, data for all patients in the study at that point (n = 363) were collected and analyzed, including basic patient characteristics, as well as comorbid disease, chronic kidney disease etiology, biochemistry data, residual renal function, total clearance function, ESA dosage, and medications administered, including iron, oral vitamin D, and phosphate binders ( month inclusion period were excluded. Time to death from any cause was the primary outcome in the 2-year observation period. Additionally, peritoneal dialysis-related peritonitis and hospitalization causes during the 2-year observation period were analyzed.
Assessment of hemoglobin variability
Hemoglobin levels were grouped according to categories described by Ebben and colleagues and were classified as low (11.0 g/dL), (10) within target (11.0 to 12.5 g/dL), or high (12.5 g/dL) from April 1, 2008 to September 30, 2008. To assess the frequency and size of the fluctuations in hemoglobin levels over time, we defined the following 6 groups of patients on the basis of their overall pattern of fluctuation: HA group (high-amplitude fluctuation; low, target-range, and high hemoglobin levels within the 6 month period), high group (consistently high levels for the entire 6 months), Target group (consistently within the target range for the entire 6 months), Low group (consistently low for the entire 6 months), LAH group (low-amplitude fluctuation with high hemoglobin levels; target-range or high hemoglobin levels within the 6-month period), and LAL group (low-amplitude fluctuation with low hemoglobin levels; low or target-range hemoglobin levels within the 6-month period) (Fig. 2) .
Adequacy of peritoneal dialysis
Weekly total Kt/V urea and weekly total creatinine clearance (CCr) were calculated from dialysate and urine collected over a 24-h period. The distribution volume of urea (V) was calculated using the Watson equation. (17) Weekly renal Kt/V urea and weekly renal CCr were used to assess residual renal function.
Statistical analysis
Descriptive statistics are presented as mean SD. All variables were tested for normal distribution using the Q-Q plot and Kolmogorov-Smirnov test. Means of continuous and categorical variables were compared across groups on the basis of hemoglobin variability using the Kruskal-Wallis test, chi-square
HA group
High group Target group test, and Fisher's exact test. The Bonferroni adjustment was used for multiple significant findings for results of multiple comparisons. Patient survival was estimated using Kaplan-Meier methods to evaluate survival to 24 months. Survival curves by hemoglobin categories were compared using the log-rank test. Peritonitis and hospitalization were assessed for relationship to hemoglobin variation pattern by the incidence rate. All statistical analyses were performed using SPSS 18.0 and R 2.11.0.
LAL group LAH group Low group
Hgb (g/dL) Hgb (g/dL) Hgb (g/dL) Hgb (g/dL) Hgb (g/dL) Hgb (g/dL)
RESULTS

Patient characteristics
Data were received from 363 peritoneal dialysis patients during the entire six months (April 2008 to September 2008) and at least 3 or more hemoglobin values were obtained; for most subjects, monthly lab data (six values) were obtained in our hospital. Patients were followed for a 2-year observation period. Table 1 describes the baseline characteristics, comorbid disease, and etiology of chronic kidney disease. Only 2% of patients maintained stable hemoglobin levels within the target range while 46.8% of the patients exhibited consistently low hemoglobin levels during the observation period. There was a higher prevalence of glomerulonephritis (46%) than diabetic mellitus nephropathy (13.5%) in the peritoneal dialysis patient population. Table 2 shows the patient biochemistry laboratory data and medication use. The ESA total dose per month was limited by medical policy; therefore there was no ESA use in the high group. Other medications were used according to current clinical practice guidelines.
Primary outcome
After the complete follow-up of 2 years, there were 23 deaths (6.3%) in the total peritoneal dialysis population. Using Kaplan-Meier analysis and comparisons with the log rank test (p = 0.833), there were no significant differences associated with mortality between hemoglobin variability categories (Fig. 3) . Cardiovascular disease (19%) and infection (23.8%) were the main causes of mortality.
Peritonitis and hospitalization results are shown in Table 3 . There were no significant differences in peritonitis incidence, hospitalization, or rates of admission for infection between hemoglobin vari- 
DISCUSSION
Our results showed no differences among the 6 groups of patients in comorbid disease, chronic kidney disease etiology, albumin, total cholesterol, potassium, calcium, intact parathyroid hormone, transferrin saturation, and oral medications (iron agents, ACEi/ARB, vitamin D, phosphate binders). ESA use in each group reflected the differences in the mean hemoglobin values. After 2 years observation, we conclude that hemoglobin variability cannot independently predict mortality in peritoneal dialysis patients. In related complications, including peritonitis, hospitalization, and the rate of hospitalization due to infection, the differences between the hemoglobin variability groups also did not reach statistical significance. However, the increase in the average hospital stay for the HA group was statistically significant.
Clinically, anemia in chronic kidney disease is affected by many factors, including factors related to patient characteristics, iron deficiency, infection, inflammation, malignancy, and, most importantly, guidelines on ESA dosage and frequency of administration. Recently, one study suggested that discontinuation rather than reduction of ESA treatment was more appropriate for hemodialysis patients when hemoglobin levels > 13 g/dL were observed. (18) Therefore, we often adjust the ESA dosage according to the mean hemoglobin level and ignore real hemoglobin cycling and hemoglobin excursions. (9) Hemoglobin overshooting may be associated with various complications, including hypertension, (19) high platelet counts, (20) and thrombotic events. (21) Our study showed a significantly reduced ESA dosage in patients who maintained low amplitude in conjunction with high hemoglobin levels (LAH group), while patients exhibiting high amplitude in conjunction with average hemoglobin levels within the target range (HA group) had ESA usage similar to that of other groups. In addition, lower ferritin was also noted in the higher mean hmoglobin levels in the high, target and LAH groups, which is compatible with clinical observation with ferritin utilization. On the other hand, patients in the target group had better residual renal function compared with those in the other groups, possibly because they had more preserved renal function which influenced the hemoglobin fluctuation.
Hemoglobin levels change over time, and one study showed that only about 5% of ESRD patients maintained target levels after a few months of observation. (8) Another study reported that over 90% of patients experienced hemoglobin cycling. (10) The mean number of hemoglobin excursions was 3.1 1.1 per patient/year. The mean amplitude per hemoglobin excursion was 2.51 0.89 g/dL and the mean duration of hemoglobin excursions was 10.3 5.1 weeks. (9) These fluctuations inhemoglobin levels in ESRD patients are distinct from normal physiological changes, leading to speculation that substantial short-term changes in hemoglobin levels and administration of high dosage ESA are two factors likely to affect prognosis. As described above, the large amplitude and periodicity changes in hemoglobin levels in patients differed significantly from levels within the narrow K/DOQI hemoglobin range. In a previous study in hemodialysis and chronic kidney disease patients using multiple calculation methods, hemoglobin variability was demonstrated to significantly affect the prognosis. Survival analyses indicat- ed that each 1 g/dL increase in the residual standard deviation was associated with a 33% increase in the rate of death. (11) In another study, hemoglobin variability was also shown to correlate with comorbidity and the rate of complications. (10) In patients with chronic kidney disease, the same phenomenon was observed. (15) While disrupted hemoglobin levels are an important symptom in patients with chronic kidney disease and ESRD, a recent large-scale study in Europe showed that hemoglobin variability does not independently predict mortality in hemodialysis patients. (16) The association between hemoglobin variability and comorbidity/mortality in peritoneal dialysis patients has not been addressed before. In this study, we found that hemoglobin variability is not an independent predictor of clinical outcome in peritoneal dialysis patients. One possible reason for this finding is the inclusion of a high proportion of patients with glomerulonephritis in this study. Patients with glomerulonephritis have shown better outcomes than those with diabetic nephropathy in previous studies, which could have affected our results. On the other hand, because most peritoneal dialysis patients maintain residual renal function, they have a better prognosis than hemodialysis patients. In our study, only 2% of the patients maintained a target level of hemoglobin, partly because of the impact of health care policy that limits ESA use. In studies from other countries, higher doses of ESA were used, which may have been more effective in maintaining target levels of hemoglobin in 5-18% of those patients, and may have affected their outcomes. (10) Most mortality cases in our study occurred in the low and LAL groups, suggesting that lower hemoglobin levels correlate with higher mortality. This is consistent with previously reported findings. It should be noted that the small number of deaths in our study compared with a previous peritoneal dialysis survival analysis in Taiwan (2-year survival rate: 77.6%) may have affected our results. (22) The deaths observed were mainly due to infections and cardiovascular disease, which accounted for 23.8% and 19% of deaths, respectively.
Peritoneal dialysis patients have more peritonitis complications than hemodialysis patients. There was no difference in the peritonitis incidence rate between the groups in our study (95% CI). Thus, the incidence of peritonitis was not affected by hemoglobin variability. Similarly, the overall hospitalization rate and the rate of hospitalization due to infection did not show differences between the groups with different hemoglobin levels. Our finding that patients in the HA group had a longer hospital stay could be explained by a higher rate of chronic inflammation or a poorer medical response in patients with greater fluctuation of hemoglobin.
There were several limitations in this study. First, the number of subjects was relatively small compared with previous hemodialysis studies. Second, because of the impact of medical policy, ESA use was limited, although few patients exhibited high hemoglobin levels; it is also possible that the high ESA dosage reported in previous studies may have affected patient outcomes, or that Asians have a different ideal range of hemoglobin compared with patients from other geographic areas. Third, our study of peritoneal dialysis patients included a larger population of patients with glomerulonephritis than with diabetes mellitus nephropathy, possibly beause of patient selection or convenience of medical care in Taiwan. Fourth, a 2-year follow-up period may not be long enough. Fifth, because this is a retrospective study, more research is needed to further analyze different formulations of ESA. Also, differences in heterogeneous distribution between our patient groups may have been related to ESA policy or other factors. Ebben et al's study also noted heterogeneous distribution even in a large study population (low: 1.8%, target: 6.5%, high: 2.0%, LAL: 21.3%, LAH: 28.9% and HA: 39.5% n = 152,846). (10) Sixth, owing to multiple factors influencing mortality in our study, the hmoglobin fluctuation in the inclusion period may not have been a good predictor of mortality in peritoneal dialysis patients. Of course, our study has limitations in that data were collected retrospectively in one medical center and the obtained database therefore reflected only a small sample of the entire Taiwan dialysis population. We will further use the basis of our study to collect more patients to overcome the heterogeneous distribution of patient groups.
In conclusion, our preliminary study demonstrates that hemoglobin variability does not independently predict mortality in peritoneal dialysis patients. There also were no significant differences in peritonitis and hospitalization rates. However, the hospital stay was longer in the HA group. 
